BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 9669503)

  • 1. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
    Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
    Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
    Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
    Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YC-1, a novel activator of platelet guanylate cyclase.
    Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
    Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
    Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of inhibition of platelet aggregation by HCL-31D.
    Chou TC; Li CY; Lee AR; Wu TM
    Eur J Pharmacol; 2000 Jan; 387(2):125-31. PubMed ID: 10650152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
    Hagiwara M; Endo T; Kanayama T; Hidaka H
    J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotides and platelet aggregation. Effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymes.
    Barber AJ
    Biochim Biophys Acta; 1976 Sep; 444(2):579-95. PubMed ID: 9149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
    Liao CH; Ko FN; Wu CL; Teng CM
    J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
    Matsuoka I; Suzuki T
    J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
    Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
    Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
    Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
    Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of demethyldiisoeugenol.
    Liao CH; Ko FN; Kuo YH; Teng CM
    Can J Physiol Pharmacol; 1996 Oct; 74(10):1111-6. PubMed ID: 9022830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
    Yu SM; Kuo SC
    Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
    Azuma H; Takashima Y; Ishikawa M; Yamakado T
    Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PP1D-1, a synthetic antiplatelet compound, on rabbit platelets.
    Liao CH; Ko FN; Kuo SC; Teng CM
    Jpn J Pharmacol; 1998 Feb; 76(2):141-8. PubMed ID: 9541276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cyclic AMP and cyclic GMP in Morris hepatomas and liver.
    Hickie RA
    Adv Exp Med Biol; 1977 May 22-24; 92():451-88. PubMed ID: 24988
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.
    Chou TC; Lin YF; Wu WC; Chu KM
    Br J Pharmacol; 2008 Mar; 153(6):1281-7. PubMed ID: 18264124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.